Pharma contracting giant AmerisourceBergen is ditching its commercial packaging business, selling the unit to Frazier Healthcare for $308 million in cash.
CROs competing for big-name deals may face a more crowded market now that on-the-ropes diagnostics companies are getting into the clinical research game, something LabCorp demonstrated this week as it inked a preferred-provider contract with Bristol-Myers Squibb.
CROs have a turnover rate nearly 10 times the national average, according to a new survey, and those numbers could scare off potential clients concerned about a company's internal climate.
U.S. CRO Frontage has received a Form 483 from the FDA after an inspection of its bioanalytical lab in Shanghai.
France's Biotrial Research has been busy salvaging usable parts from the CRO graveyard, first buying Warnex's defunct bioanlytics business and now picking up CNS technology and expertise from the liquidating Forenap.
Florida's bioRASI has completed its acquisition of Sponsors Clinical Research Group, planning to integrate the Ukraine company's capabilities and client roster into its growing Eastern European market share.
ReSearch Pharmaceutical Services is teaming up with Japan's Asklep to kick off a joint venture targeting the country's growing biotech and medical device industries.
India's struggles to regulate its booming clinical research industry are well told, but now China could be headed down the same path, as a Beijing court has taken issue with how trial-runners pay compensation to patients.
DKSH, a pharma market-services contractor, has re-upped with Bayer Healthcare to help the drug giant expand its presence in Cambodia, agreeing to handle importation, regulatory clearance and distribution in the Asian nation.
France's Sanofi is expanding its contract manufacturing capabilities, teaming up with Transgene to spend $13 million on a new CMO platform.
When CRO Cetero Research crashed and burned after a falsified data scandal, its new owners rebranded it PRACS Institute and tried to give contract research another go on the straight and narrow. That effort has apparently failed, however, as the company reportedly shut down with almost no notice to employees, sponsors or patients.
More and more research universities are jumping into the CRO game, using their existing labs and expertise to launch moneymaking operations. Duke University's clinical research unit has signed on with Benitec Biopharma to run Phase I/II trials for an RNAi hepatitis C drug.
Indian generics giant Dr. Reddy's Laboratories has wrapped up its lawsuit against Nordion, agreeing to a $22.5 million settlement with the former CRO.
Chinese CRO ShangPharma won shareholder approval for its effort to get off the New York Stock Exchange and go private, a plan that involves selling the company to private equity firms and some of the CRO's leadership.
Sunshine Biopharma is eyeing a Phase I trial of its Adva-27a treatment for drug-resistant breast cancer, and the company is in talks to find a CMO partner.
Toxicology specialist Calvert Labs is joining forces with the formulation experts at Particle Sciences to offer an early-stage service package designed to speed up drug development.
India's government is taking seriously the call to better regulate clinical trials, and now the country is planning to launch two independent committees tasked with overseeing the process.
A U.K. court has convicted a former Aptuit employee of manipulating data from hundreds of safety studies, making investigational drugs seem successful when they weren't.
Earlier this month, Radiant Research exited the CRO business, as parent company Clinical Research Advantage shipped out its drug development arm. Now the company is focusing on its remaining core business: maintaining and expanding a network of clinical trial sites.
Two private equity firms are pooling their CRO resources, agreeing to merge the formerly public BioClinica with imaging and cardiac safety contractor CoreLab.